These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 2627607

  • 1. Treatment of refractory acute leukaemia with aclacinomycin A.
    Rowe JM, Chang AY, Bennett JM.
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():47-8. PubMed ID: 2627607
    [No Abstract] [Full Text] [Related]

  • 2. Aclacinomycin, cytosine arabinoside and thioguanine in relapsed or resistant acute myeloid leukemia.
    Neri A, Comis M, Brugiatelli M, Martino B, Ronco F.
    Haematologica; 1989 Dec; 74(1):113-4. PubMed ID: 2498174
    [No Abstract] [Full Text] [Related]

  • 3. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Sung WJ, Kim DH, Sohn SK, Kim JG, Baek JH, Jeon SB, Moon JH, Ahn BM, Lee KB.
    Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
    [Abstract] [Full Text] [Related]

  • 4. Treatment of relapsed and refractory acute myelogenous leukaemia with aclacinomycin A (ACA) and etoposide (VP-16).
    Hilbe W, Thaler J, Eisterer W, Ludescher C, Niederwieser D.
    Leuk Res; 1994 Sep; 18(9):655-8. PubMed ID: 7934139
    [Abstract] [Full Text] [Related]

  • 5. Preliminary results of an induction combination regimen including fractionated anthracycline.
    Krieger O, Bernhart M, Fiedler E, Kasparu H, Weber E, Lutz D.
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():66. PubMed ID: 2627610
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A].
    Beck JD.
    Monatsschr Kinderheilkd; 1986 Aug; 134(8):547-9. PubMed ID: 3464845
    [Abstract] [Full Text] [Related]

  • 8. [Chemotherapy of relapsed AML and ALL].
    Nishikawa K.
    Rinsho Ketsueki; 1996 Aug; 37(8):647-50. PubMed ID: 8827871
    [No Abstract] [Full Text] [Related]

  • 9. [Preliminary treatment results of relapsed or refractory acute leukemia using two and three drug regimens].
    Mariańska B, Apel D, Seferyńska I, Maj S.
    Wiad Lek; 1998 Aug; 51(1-2):42-5. PubMed ID: 9608830
    [Abstract] [Full Text] [Related]

  • 10. Secondary acute myeloblastic leukemia in a child with acute lymphoblastic leukemia treated with epipodophyllotoxins.
    Ozbek N, Cetin M, Tuncer AM, Yetgin S.
    Turk J Pediatr; 1995 Aug; 37(3):279-82. PubMed ID: 7502369
    [Abstract] [Full Text] [Related]

  • 11. Mitoxantrone and cytosine arabinoside (ARA-C) in adult acute leukemia: an interim report.
    Kansu E, Koc Y, Kars A, Alakavuklar M, Tekuzman G, Firat D.
    J Chemother; 1989 Jul; 1(4 Suppl):1268-70. PubMed ID: 16312861
    [No Abstract] [Full Text] [Related]

  • 12. Comparative evaluation of response to intensive chemotherapy in acute leukaemic patients.
    Mód A, Tamáska J, Poros A, Király A, Adám E, Gidáli J, Hollán SR.
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():24. PubMed ID: 2627605
    [No Abstract] [Full Text] [Related]

  • 13. [Investigations in the use of mogramostime (GM-CSF) in patients with acute leukemia].
    Paśnicki M.
    Wiad Lek; 1995 Dec; 48(1-12):194-7. PubMed ID: 9638239
    [No Abstract] [Full Text] [Related]

  • 14. ["AB-Triple V" therapy of relapsed or refractory acute myelogenous leukemia].
    Asou N, Suzushima H, Hamasaki N, Goto J, Hidaka M, Akagi K, Kurisaki H, Sawatari T, Kawano F, Takatsuki K.
    Rinsho Ketsueki; 1989 Feb; 30(2):169-74. PubMed ID: 2746873
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [BH-AC.AMP protocol in the treatment of refractory childhood acute leukemia].
    Nakadate H, Hatayama Y, Hatae Y, Takeda T.
    Gan To Kagaku Ryoho; 1988 Oct; 15(10):2907-10. PubMed ID: 3178240
    [Abstract] [Full Text] [Related]

  • 17. rHuGM-CSF after high-dose chemotherapy in post-remission acute leukemia.
    Hurtado R, Candelaria M, Vargas F, Majluf A, Bolaños F, Labardini JR.
    Stem Cells; 1995 Mar; 13(2):112-22. PubMed ID: 7787778
    [Abstract] [Full Text] [Related]

  • 18. [Experience with using aclarubicin in the treatment of acute leukemia and blast crisis of chronic myeloid leukemia].
    Savchenko VG, Isaev VG, Abakumov EM, Khoroshko ND, Turkina AG, Sokolov AN, Viadro MM, Navashin SM.
    Antibiot Khimioter; 1992 Jul; 37(7):47-9. PubMed ID: 1456812
    [Abstract] [Full Text] [Related]

  • 19. [Inefficiency of cisplatin and epidoxorubicin as a treatment in resistant adult acute lymphoblastic leukemia].
    Avilés A, Rubio ME, Tripp F, González-Llavén J.
    Sangre (Barc); 1988 Dec; 33(6):522-4. PubMed ID: 3247627
    [No Abstract] [Full Text] [Related]

  • 20. Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide.
    Maia RC, Carriço MK, Klumb CE, Noronha H, Coelho AM, Vasconcelos FC, Ruimanek VM.
    J Exp Clin Cancer Res; 1997 Dec; 16(4):419-24. PubMed ID: 9505216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.